{"analyses":[{"ciLowerLimit":"0.673","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.577","estimateComment":"Log-rank test stratified by:\\* Region (Asia vs Non-Asia), \\* Number of organs with metastatic sites (0 to 2 vs \\>= 3), \\* Prior gastrectomy (Yes or No)","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4478","paramType":"Hazard Ratio (HR)","paramValue":"1.030","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Data was not estimable because less than 50% of participants had event (data was estimated using KM and it requires at least 50% of event to be able to calculate time using KM.","groupId":"OG000","lowerLimit":"28.16","upperLimit":"NA","value":"NA"},{"comment":"The lower bound of the confidence interval for the median survival time may not be estimable, even if the median itself can be calculated, in scenarios with significant early censoring and a limited number of events","groupId":"OG001","lowerLimit":"18.46","upperLimit":"NA","value":"25.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"253"}],"units":"Participants"}],"description":"TTCD:time from randomization to first CMFD confirmed at next scheduled visit.OG25 evaluated gastric \\& gastroesophageal junction cancer-specific symptoms,had 25 items with 6 scales:dysphagia,eating restrictions,reflux,odynophagia,pain, discomfort,anxiety,and 10 single items:trouble with(taste, swallowing saliva, coughing, talking),eating in front of others,dry mouth,body image,choked when swallowing,weight loss and hair loss. STO22: gastric cancer quality of life questionnaire with 22 questions.For OG25 and STO22,items scored on(1:not at all; 2:a little, 3:quite a bit, 4:very much) and 1 question was \"yes or no\" for STO22.Linear transformation was used; score ranged from 0 to 100; higher score=better level of functioning or greater degree of symptoms. An item from STO22 instrument related to belching was used with OG25. CMFD: if participant's CFB exceeded pre-specified threshold (per investigator's discretion) denoting a clinically meaningful change. Kaplan-Meier estimates was used","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an intravenous (IV) infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 milligrams per square meter (mg/m\\^2) on cycle 1 day 1 (C1D1) followed by subsequent doses of 600 mg/m\\^2 every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of capecitabine and oxaliplatin (CAPOX) treatment. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 twice daily (bid) on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21","id":"OG000","title":"CAPOX+ Zolbetuximab"},{"description":"Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of CAPOX. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 bid on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21 days.","id":"OG001","title":"CAPOX+ Placebo"}],"paramType":"MEDIAN","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"From the date of randomization until 61 months and 12 days","title":"Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25 Plus STO22 Belching Subscale","type":"SECONDARY","unitOfMeasure":"Months"}